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Recent advancements to enhance the therapeutic efficacy 
of antiepileptic drugs
Epilepsy is a multifactorial neurological disorder charac-
terized by recurrent or unprovoked seizures. Over the past 
two decades, many new antiepileptic drugs (AEDs) were 
developed and are in use for the treatment of epilepsy. 
However, drug resistance, drug-drug interaction and ad-
verse events are common problems associated with AEDs. 
Antiepileptic drugs must be used only if the ratio of efficacy, 
safety, and tolerability of treatment are favorable and out-
weigh the disadvantages including treatment costs. The 
application of novel drug delivery techniques could en-
hance the efficacy and reduce the toxicity of AEDs. These 
novel techniques aim to deliver an optimal concentration of 
the drug more specifically to the seizure focus or foci in the 
CNS without numerous side-effects. The purpose of this 
article is to review the recent advancements in antiepileptic 
treatment and summarize the novel modalities in the route 
of administration and drug delivery, including gene therapy, 
for effective treatment of epilepsy.
Keywords: antiepileptic drugs, drug delivery, epilepsy, gene 
therapy, liposomes, nanoparticles
INTRODUCTION
Epilepsy is a chronic neurological disorder that affects people of all ages and races 
with a high incidence in elderly people and children. According to the WHO factsheet 2019 
(1), about 50 million people worldwide have epilepsy. The pooled incidence rate of epi-
lepsy was 61.4 per 100,000 persons per year, and its incidence was even higher in low/
middle-income countries (~80 %) than in high-income countries (2). Epilepsy is character-
ized by repeated seizures resulting from recurrent, abnormal, excessive synchronous dis-
charges of cerebral neurons. Epilepsy can be caused by stroke, genetic disorder, brain 
 tumor or infection, and brain injury. There is no clinical confirmation, however, that 
 epilepsy patients infected with COVID-19 or any other infectious disease may have a fever 
which may trigger seizures (3). Antiepileptic drug (AED) therapy is the mainstay of treat-
ment for most patients, but in some cases, brain surgery may be required. Approximately 
70 % of cases of epileptic seizures are controlled with AEDs, albeit with some side-effects 
(4). The International Board against Epilepsy (ILAE) and the International Bureau of 
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 Epilepsy (IBE) defined epileptic seizures as a transient occurrence of signs and/or 
 symptoms due to abnormal excessive or synchronous neuronal activity in the brain (5). 
The main factors involved in the pathophysiology of seizures are: (i) abnormalities in the 
hippocampus region of the brain, (ii) imbalance in the excitatory and inhibitory neuronal 
systems along with the generation of a burst discharge from a neuron, and (iii) impairment 
of gamma-aminobutyric acid (GABA) inhibitory system (6). Based on seizure origin, 
 epilepsy is classified into two types: (i) partial (focal) seizures and (ii) generalized seizures. 
The diagnosis of epilepsy is generally based on the results of electro-encephalography 
(EEG), high-resolution cerebral magnetic resonance imaging (MRI) and cerebrospinal 
fluid (CSF) analysis. The choice of treatment mainly depends on an accurate diagnosis of 
epilepsy syndrome based on careful patient history and findings by EEG and MRI (7). 
Over the past few years, many new AEDs have been developed and are in use for antiepi-
leptic treatment (8, 9). Treatment options have increased dramatically since the 1990s with 
the introduction of new generation AEDs such as vigabatrin, felbamate, gabapentin, 
 lamotrigine, tiagabine, topiramate, levetiracetam, oxcarbazepine, zonisamide, pregabalin, 
rufinamide, and lacosamide. The newer generations of drugs are more efficacious demon-
strating better safety and tolerability profiles compared with the older generation drugs 
such as phenobarbital, phenytoin, carbamazepine and valproate. The mechanism of anti-
epileptic drugs acting is depicted in Fig. 1 and categorized in Table I.
However, despite the availability of several new AEDs in the market, many patients 
still have seizures either because they do not respond to these medications or have related 
side-effects that prevent continued use of these medications. Even in patients in whom 
antiepileptic pharmacotherapy is efficacious, current AEDs do not affect the progression 
of epilepsy. Furthermore, there is currently no AED available which prevents the develop-
ment of epilepsy.
Adherence to medication forms an important part of the patient’s care and is essential 
for reaching clinical goals. Initiation and termination of the treatment and adherence 
Fig. 1. The mechanism of action of antiepileptic drugs. Taken from resources at The Royal Children’s 
Hospital, Melbourne, Australia (www.rch.org.au), with permission.
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 assessments are important tools for epileptic disease management. Therefore, it is impor-
tant to evaluate any patient comorbidity, especially psychiatric comorbidities, before and 
after choosing AEDs (8). Currently, there is no proper evidence that could prove that 
 current AEDs could prevent or reduce drug resistance in patients (10). The fact that  epilepsy 
is heterogeneous with enormous variations in etiology and clinical features makes it 
 unlikely that a single drug could eradicate refractory epilepsy.
Given the high cost of clinical drug development, research organizations are empha-
sizing the development of novel drug delivery methods that could enhance efficacy and 
reduce the toxicity of AEDs (11). One of the major challenges in drug delivery to the brain 
is the presence of a blood-brain barrier (BBB) which is the major route for the uptake of 
different substances such as serum ligands (12). The relative impermeability of the BBB is 
due to the presence of tight junctions that form impermeable seals between capillary endo-
thelial cells. Recently, many new strategies have been developed to increase the penetration 
of AEDs in the brain parenchyma.
In this review, we discuss the recent developments in the field of drug delivery for the 
treatment of epilepsy. We are also reviewing new therapeutic compounds that are in the 
clinical pipeline, or currently in the clinical evaluation stage for the cure of epilepsy and 
its symptoms. The recent advancement in antiepileptic treatment can be divided into four 
categories: (i) new antiepileptic drugs, (ii) novel delivery approaches, (iii) novel route appro-
aches, (iv) gene therapy.
CURRENT ANTIEPILEPTIC DRUGS
Paraldehyde was the first AED that was introduced in 1882, and since then many new 
drugs have been developed to reduce seizure frequency and to achieve seizure freedom in 
patients. Currently available antiepileptic drugs are listed in Table I, and few newer drugs 
which are presently under clinical development phases are listed in Table II. The choice of 
AED depends on several factors such as seizure type, presence of an epilepsy syndrome, 
other medications, comorbidities, lifestyle, and patient preference. As per the literature, 
antiepileptic monotherapy should start when the initial treatment fails to control seizures. 
Subsequent management should be undertaken when the initial monotherapy also fails to 
produce the desired action (13). Carbamazepine is the drug of choice for focal onset sei-
zures, while divalproex sodium is used for generalized seizures.
NOVEL DELIVERY APPROACHES
Theoretically, direct delivery of AEDs to the CNS has a higher therapeutic-toxic ratio 
than the systemic drugs. However, several possible methods have been established for the 
direct delivery of AEDs to the CNS (14, 15).
Convection-enhanced delivery (CED)
CED facilitates the targeted delivery of drugs to the brain (16). CED is a promising 
technique that uses positive hydrostatic pressure to deliver therapeutics into the intersti-
tial space within a localized region of the brain parenchyma. CED circumvents the BBB 
and provides a homogenous distribution than bolus deposition (focal injection) or any 
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other diffusion-based delivery approach. CED avoids the systemic toxicities of orally admini-
stered AEDs and bystander effects on non-epileptic brain regions. In a typical CED 
 application, the drug is dissolved in a saline solution and is delivered by slow infusion 
under positive pressure through a fine cannula (17, 18).
Drug delivery by liposome
Liposomes are microscopic spherical vesicles consisting of a phospholipid bilayer that 
is used to encapsulate chemical compounds. In this form, the vehicle is able to release the 
drug in a steady manner over a long period of time. The liposome can bind to a specific 
receptor in the region of interest and the drug entrapped in the liposome is delivered into 
the brain where seizures were generated. Difficulty in drug penetration across the BBB is 
one of the major limitations of liposomes (19).
Nanoparticles
Nanoparticle drug delivery systems use nanoparticles for the targeted delivery and con-
trolled release of therapeutic agents. Nanoparticles could also be used for AEDs delivery to 
the brain, in which the drug is encapsulated within a nanoscale delivery system. The nanopar-
ticles are composed of biodegradable polymers with a size ranging from 10 to 1000 nm. 
 Examples of polymers used in nanoparticle formulations include poly(lactic-co-glycolic acid) 
(PLGA), which is used more frequently due to its biocompatibility and safety. Some 
 researchers reported that the degradation property of poly(lactic-co-glycolic) acid can be 
 controlled by changing the ratio of the copolymer (20, 21). The therapeutic efficacy of etho-
suximide-loaded nanogel in a rat model using the depot drug delivery technique showed a 
promising alternative to available ethosuximide formulation (22).
By using the bio-conjugation technique, polymers can be conjugated to the liposomal 
surface and nanoparticles to increase its biological half-life in the systemic circulation. 
These polymer chains form a ‘stealth’ like structure, thus the particles are no longer opso-
nized and increase the circulation time. Examples of such polymers are polyvinyl alcohol, 
polysaccharides, polyethylene glycol (PEG), and poly-acrylamide. To produce stealth-like 
particles, PEG is preferred due to its hydrophilic nature. PEG attaches to the colloidal car-
rier surface by adsorption, physical entrapment, and/or covalent attachment and protects 
the plasma protein from the opsonization process. However, it is uncertain whether PEG, 
which can increase the circulation time of AEDs after intravenous injection, can also cross 
the BBB. The PEG-based nanoparticle may be conjugated with a targeting moiety (cell-
pene trating peptides) to facilitate the passage of AEDs across the BBB.
Efflux pumps
With the addition of some biochemical substances to the drug delivery system, the 
permeability of the drug across BBB can be increased. Examples of such compounds in-
clude multidrug resistance-associated proteins (MRPs), P-glycoprotein (PgP) and breast 
cancer resistance proteins (BCRP). These proteins belong to the superfamily of ATP bind-
ing cassette (ABC) transporter, expressed in the neurons, endothelial cells, and epilepto-
genic brain tissue in patients with intractable epilepsy. It hydrolyzes ATP to transfer mole-
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cules into the systemic circulation against their concentration gradient, and by doing this 
affects drug localization into the CNS.
The literature showed that anticonvulsant treatments can be improved by blocking 
the ABC transporter system in the brain. For example, verapamil (calcium channel blocker) 
inhibits the pumping action of PgP, thus a greater control in seizure is experienced by 
patients who use verapamil and AEDs. The disadvantage of this method includes the vari-
able ability of efflux pumps to transport the substrate from species to species and all the 
AEDs are not proper substrates for PgP, MRPs, and BCRP. More investigations are under-
taken to understand the particular mechanism of efflux pumps on AEDs (23).
Drug wafer
A drug wafer consists of an interwoven AED in a polymer matrix. In these formula-
tions, the polymers are dissolved with the drug and it slowly releases the medication for a 
month or years. Nowadays, neurologists and neurosurgeons use the drug wafer such as 
BCNU-containing gliadel wafer also for tumor resection. The efficacy of phenytoin was 
investigated by Tamargo et al. (24) and to prove the same, they used a cobalt-induced rat 
model for epilepsy and phenytoin as a drug wafer which was administered through the 
intra-cerebral route. The drug (phenytoin) was slowly released up to a period of 4 months; 
as a result, there was progress in the behavioral seizure scale in comparison to animals 
who received drugs without drug wafer. The main drawback of drug wafers includes low 
potencies, low solubility, and the drug-releasing capacity was also nonlinear which could 
provide a narrow therapeutic ratio.
Perfusion by catheters
In this method, a catheter and a pump are used to deliver an AED. The catheter is 
 attached to a pump to infuse the drug at a constant rate. Eder et al. (25) designed a rat 
model to study this drug delivery system. In order to evaluate this system, a small bone 
window was designed in the left parietal region of the rat, and an AED (bicuculline 
methiodide) was administered which generated an epileptic form spike.
Pro-drugs
The pro-drug (inactive form) is converted into an active form of the drug and a non-
toxic moiety after biotransformation. The pro-drugs are attached to a distinct compound 
that is removed via hydrolysis (in vivo) or enzymatic cleavage. The pro-drug can cross the 
BBB because of the attached moiety, thereby making the pro-drug more lipophilic. A pro-
drug of valproic acid, named DP-VPA (DP16) is prepared by linking VPA and lecithin (a 
phospholipid), which gets activated in the systemic circulation. The active drug (valproic 
acid) is released by phospholipase A2 following the cleavage of lecithin. Using this method, 
the valproic acid becomes overactive and can reach the target site more efficiently  compared 
with plain valproic acid. Systemic toxicity is greatly reduced by limiting the activation of 
pro-drug to the seizure focus. After cessation of seizure, the over activation of pro-drug is 
prevented, since the neurons exit their excited state and the enzymatic activity is decreased 
(26).
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Hyperosmolar BBB opening
The osmolarity of the blood flowing through the capillary of the brain can be in-
creased by altering the function of the BBB. A hyperosmolar solution such as mannitol (25 %) 
when administered intra-arterially reduces the size of the brain capillary (endothelial 
cells). Thus, the permeability of the BBB for AEDs may be increased by increasing the 
width of the tight junction between them. The hyper-osmotic effect on BBB opening is 
spontaneously reversible and acts for a short period of time. After the addition of mannitol, 
the permeability of the drug to the BBB gets enhanced and returns to its normal range 
after 8 h. The common side-effects of this method include edema and toxicity (27).
Monolithic devices
Monolithic devices are produced by different processes such as casting, melt extru-
sion and electrospinning method (28). These devices are applied to the brain surface or the 
brain parenchyma as pellets, rods, disks, and fibers.
NOVEL ROUTE APPROACHES
The development of medical devices opened new hope for the increased therapeutic 
efficacy of antiepileptic drugs through neuromodulation or acting directly (Table III).
Non-oral routes
Nasal/rectal routes. – The nasal mucosa can be used for non-invasive systemic admini-
stration of drugs. Water-soluble drugs such as benzodiazepine, midazolam are admini-
stered through the intranasal route. Clinical studies have proven that the intranasal admini-
stration of midazolam exerts its effects slowly compared with intravenous administration 
of diazepam in children (29). However, administration of AEDs through the nasal route 
has some major limitations as respiration becomes shallow and irregular during seizures. 
Recently, USFDA (30) has approved the rectal route for drug delivery application. In a 
comparative study of route preference among patients with epilepsy, midazolam admini-
stered through nasal route was equally efficacious to diazepam that was administered 
through the rectal route for the suppression of seizure exacerbations (31).
Trans-dermal route. – One of the most common routes for drug administration is via the 
dermal and epidermal layers of the skin. Antiepileptic drugs such as lidocaine are admini-
stered by the intradermal route. However, several clinical studies have demonstrated that 
lidocaine administration through the skin caused rapid remission of recurrent seizures 
(32, 33).
Localized routes
Intracerebroventricular administration. – In this technique, the drug is administered 
 directly into the cerebrospinal fluid (CSF) by an intracerebroventricular route in which 
an outlet catheter leading from an implantable reservoir/pump is used. Thus, problems 
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 associated with intravenous administration such as opsonization, drug metabolism, sys-
temic toxicity can be reduced. The limitations of this technique include restricted drug 
penetration into the brain parenchyma. Intracerebroventricular administration is useful 
for the local deposition of the drug at the ependymal surface of the brain, but not for drug 
delivery to cells that are far from the ependymal surface. The movement of drug molecules 
from the CSF to the brain parenchyma (by diffusion) is very low because of high tortuos-
ity that restricted the pore size of the extracellular space (34, 35).
Intracerebral administration. – Alternative method for AEDs administration in the ven-
tricle is the delivery of the drug to the parenchyma of the brain by an implant/injection. 
Studies were carried out on drugs such as adenosine, which was injected into the seizure 
focus/ventricle. The antiepileptic effect of these delivery strategies after seizure onset by 
an intra-cerebral penicillin injection has been investigated. The adenosine reduces the 
mean spike frequency, but not the amplitude. Local adenosine injection to the frontal area 
showed a reduction in the mean spike frequency and amplitude. The antiepileptic effect 
increased after drug administration, suggesting that the adenosine injection given directly 
to a seizure focus was more effective than intracerebroventricular administration (36).
Intraventricular/intrathecal route. – Drugs administered into CSF through the intraven-
tricular/intrathecal route are found to be safer compared with other routes. This route does 
not cause any surgical trauma to the brain and is considered safer compared to available 
techniques involving surgical procedures. Factors affecting CSF drug delivery include 
penetration rate and drug concentration in the brain tissue. In order to prevent seizures in 
epilepsy, the movement of medication (intrathecal/intraventricular route) must be in bulk 
convection and should penetrate faster under pressure (37). A preclinical study of AEDs 
administered through the intrathecal route in animal models produces a severe decrease 
in motor activity. Intrathecal administration of baclofen was evaluated in the reduction of 
seizure episodes in the pediatric population. About 13.3 % of pediatric patients who 
 received baclofen via the intrathecal route showed a decrease in seizure frequency (38, 39).
GENE THERAPY
Studies have shown that gene therapy can be used for the treatment of acquired and 
genetic diseases. Gene therapy can also be used to treat diseases such as cancer, hemo-
philia, AIDS, neurodegenerative disorders. Preclinical studies have shown that gene therapy 
is capable of suppressing seizures at their site of origin (40, 41).
The most common method of gene delivery to the brain involves the packaging of the 
molecular apparatus of gene expression into a deactivated viral vector, followed by direct 
focal microinjection into the relevant brain region (42, 43).
The insertion of genetic code and genetic expression depends on the ability of viruses 
to invade host cells. Viruses such as recombinant adeno-associated viruses (rAAVs) are 
used, which have low immunogenicity, prolonged-expression, and tropism for post-mitotic 
neurons. However, there could be some limitations with the selected gene for gene therapy 
approach in epilepsy for preclinical studies. The investigation started with the inhibitory 
neurotransmission activity mediated by several components like GABA, subunits of GABAa 
receptor and transduction of glutamic acid decarboxylase.
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In epilepsy, the GABA receptors are down-regulated and in some cases, loss of GABA- 
-ergic neurons causes chronic epilepsy. To overcome this condition, some endogenous 
neuromodulators like galanin, neuropeptide Y (NPY) have been used because of their 
anticonvulsant activity. These neuromodulators exert/produce their inhibitory activity on 
the presynaptic glutamate release and by gene transduction process the genetic code is 
inserted/entrapped into host neurons which results in over-expression of peptide release 
to enhance their neuroprotective activity. Gene therapy has been attempted to produce 
antiepileptogenic, antiseizure and disease-modifying effects (44).
According to Sills (45), NPY-based gene therapy provides some potential for antisei-
zure and antiepileptogenic effects. The author used an experimental model that consists 
of temporal lobe epilepsy with a short period of acute status epilepticus, induced in the 
hippocampus by electrical stimulation. After a few weeks, a 24-h video of EEG monitoring 
was recorded with an unprovoked recurrent seizure. Afterward, the NPY gene therapy 
was started with the randomized animal in which a control vector (without NPY gene) and 
the rAAV vector were given directly by microinjection (bilateral) into the hippocampus. 
Then, the rat/animal was evaluated for seizure activity by using a 24-h video of EEG after 
4 weeks. During this time the neuronal transduction and overexpression of the NPY gene 
were generated. On the other hand, the control animals developed some epilepsy with 
spontaneous seizures. The animals which were treated with NPY gene therapy showed a 
significant reduction in seizure activity. The overexpression of the NPY gene was limited/
restricted to some regions of the hippocampus, that is, the dentate gyrus. The immuno-
histochemical studies revealed that the overexpression mainly depends on the antiepilepto-
genic activity. In the immunohistochemical method, the tissue was harvested by an ex vivo 
process, using video-EEG monitoring.
In gene therapy, safety is the main concern for an epileptic patient. By reverse recom-
bination or mutagenesis process, the viral vector might be deactivated which is the main 
safety concern in gene therapy. In the long term, gene expression shows unexpected 
 adverse effects. A focal delivery through stereotaxic neurosurgery creates a barrier for the 
use of gene therapy in refractory epilepsy and those patients are unsuitable for surgery. 
Gene therapy can be applied to surgically remediable lesions to reject the injected part/
organ. However, in complex epilepsy, single-gene transduction is not enough to produce 
remarkable action.
FUTURE RESEARCH CHALLENGES
Several AEDs with superior efficacy are still under research and development. Many 
patients experience memory disorders and severe adverse effects with the use of available 
AEDs. In children, a number of epilepsy syndromes remain constant due to drug resis-
tance. The new antiepileptic drug discovery programs have relied primarily on a screening 
process by using traditional animal models that act primarily on ion channels or 
 neurotransmitter receptors. The new AEDs are discovered when new chemical entities 
were subjected to systemic testing and found by chance to have antiepileptic properties. 
Some new molecules were rationally designed in order to enhance their efficacy based on 
currently available agents to eliminate side-effects.
Apart from this, researchers need to define new targets for developing a better drug. 
For this purpose, the neurobiology of the epileptogenic region in the brain and the mech-
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anisms that lead to the emergence of epileptic seizures must be thoroughly investigated 
(46, 47). The required technological parameters for identifying new drug targets can be 
done by:
– developing the molecular and cellular analysis of tissue specimens,
– gene transfer technology,
– generation of genetically modified animals, and 
– advanced imaging and electrophysiological techniques.
CONCLUSIONS
Conventionally, antiepileptic drugs are administered by oral and intravenous routes. 
However, due to metabolic, physiological, and genetic polymorphism related limitations, 
an individualized treatment approach should be adopted for optimal management of epi-
lepsy. For epilepsy patients that do not respond well to monotherapy, a combination therapy 
must be considered; however, overtreatment should be carefully avoided due to systemic 
side-effects and neurotoxicity. Novel treatments and delivery approaches aimed at either 
disrupting or by-passing the blood-brain barrier opened a new era in the treatment of 
epilepsy. Research on human genetics also created a glimmer in this therapeutic domain 
for a more specialized approach to epilepsy treatment. Healthcare professionals and 
 patients place great hopes for better efficacy and tolerability of new antiepileptic drugs and 
delivery approaches in different clinical trials.
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Abbreviations, acronyms, symbols. – ABC – ATP binding cassette, AED – anti-epileptic drugs, 
AMPA – α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid, BBB – blood-brain barrier, BCRP 
– breast cancer resistance proteins, CED – convection-enhanced delivery, CNS – central nervous 
system, CSF – cerebrospinal fluid, EEG – electroencephalography, FACES – finding a cure for epi-
lepsy and seizures, GABA – gamma-aminobutyric acid, GPR– G-protein coupled receptor, IBE – In-
ternational Bureau of Epilepsy, ILAE – International Board against Epilepsy, MRI – magnetic reso-
nance imaging, MRPs – multidrug resistance-associated proteins, NINDS – National Institute of 
Neurological Disorders and Stroke, NMDA – N-methyl-d-aspartate receptor, NPY – neuropeptide Y, 
PEG – polyethylene glycol, PgP – P-glycoprotein, PLGA – poly(lactic-co-glycolic) acid, rAAVs – recom-
binant adeno-associated viruses, rTMS – repetitive transcranial magnetic stimulation, SV2A – syn-
aptic vesicle glycoprotein 2A, VPA – valproic acid, WAND – wireless artifact-free neuromodulation 
device.
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